[Form 4] 10x Genomics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (Ticker: TXG), reported a sale of 7,486 shares of Class A common stock on 08/22/2025 at a price of $13.787 per share. The filing states the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. After the transaction, Mr. Hindson beneficially owned 440,888 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Hindson on 08/26/2025. The filing lists Mr. Hindson as both a director and an officer of the issuer.

Positive

• Timely and transparent disclosure of insider transaction under Section 16
• Sale explicitly for tax withholding, indicating the transaction was administrative rather than discretionary
• Post-sale ownership remains substantial at 440,888 shares, suggesting continued alignment with shareholder interests

Negative

• Insider sale could be interpreted negatively by some market participants despite the stated tax purpose
• Limited context in the filing about recent vesting schedule or remaining unvested awards

Insights

Financial Analyst

TL;DR: Routine insider sale to satisfy tax withholding; not materially dilutive given holding size.

The reported sale of 7,486 shares at $13.787 to cover tax withholding tied to RSU vesting appears to be a non-discretionary, administrative transaction rather than a signal of changed conviction. Post-sale direct ownership of 440,888 shares remains substantial relative to the quantity sold. There is no indication of additional open-market selling plans or larger disposals in this filing, and the transaction size is small versus the remaining stake, suggesting limited near-term impact on capital structure or market perception.

Corporate Governance Expert

TL;DR: Filing demonstrates compliance with Section 16 reporting; sale documented as tax-related.

The Form 4 discloses the reporting persons dual role as director and officer and provides the required detail for transparency. The explanatory note explicitly states the sales purpose—covering tax withholding from RSU vesting—which is a common, permitted practice under executive compensation plans. The timely filing and attorney-in-fact signature indicate procedural adherence to reporting obligations. No governance concerns or policy breaches are evident from the disclosed transaction alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hindson Benjamin J.

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/22/2025		S(1)		7,486	D	$13.787	440,888	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

President and Chief Scientific Officer

	/s/ Eric S. Whitaker, as Attorney-in-Fact for Benjamin J. Hindson	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Benjamin J. Hindson report on Form 4 for TXG?

He reported a sale of 7,486 shares of Class A common stock on 08/22/2025 at $13.787 per share.

Why were the shares sold according to the filing?

The filing states the shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

How many shares did Hindson own after the reported transaction?

After the sale, he beneficially owned 440,888 shares, held directly.

What roles does the reporting person hold at 10x Genomics (TXG)?

The Form 4 lists him as a Director and an Officer (President and Chief Scientific Officer).

When was the Form 4 signed and by whom?

The form was signed by an attorney-in-fact, Eric S. Whitaker, on behalf of Benjamin J. Hindson on 08/26/2025.